Correlation Between Lexicon Pharmaceuticals and Puma Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Lexicon Pharmaceuticals and Puma Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lexicon Pharmaceuticals and Puma Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lexicon Pharmaceuticals and Puma Biotechnology, you can compare the effects of market volatilities on Lexicon Pharmaceuticals and Puma Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lexicon Pharmaceuticals with a short position of Puma Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lexicon Pharmaceuticals and Puma Biotechnology.

Diversification Opportunities for Lexicon Pharmaceuticals and Puma Biotechnology

-0.49
  Correlation Coefficient

Very good diversification

The 3 months correlation between Lexicon and Puma is -0.49. Overlapping area represents the amount of risk that can be diversified away by holding Lexicon Pharmaceuticals and Puma Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Puma Biotechnology and Lexicon Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lexicon Pharmaceuticals are associated (or correlated) with Puma Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Puma Biotechnology has no effect on the direction of Lexicon Pharmaceuticals i.e., Lexicon Pharmaceuticals and Puma Biotechnology go up and down completely randomly.

Pair Corralation between Lexicon Pharmaceuticals and Puma Biotechnology

Given the investment horizon of 90 days Lexicon Pharmaceuticals is expected to generate 2.39 times more return on investment than Puma Biotechnology. However, Lexicon Pharmaceuticals is 2.39 times more volatile than Puma Biotechnology. It trades about 0.11 of its potential returns per unit of risk. Puma Biotechnology is currently generating about -0.04 per unit of risk. If you would invest  69.00  in Lexicon Pharmaceuticals on October 5, 2024 and sell it today you would earn a total of  9.00  from holding Lexicon Pharmaceuticals or generate 13.04% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Lexicon Pharmaceuticals  vs.  Puma Biotechnology

 Performance 
       Timeline  
Lexicon Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Lexicon Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Puma Biotechnology 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Puma Biotechnology are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady basic indicators, Puma Biotechnology demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Lexicon Pharmaceuticals and Puma Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Lexicon Pharmaceuticals and Puma Biotechnology

The main advantage of trading using opposite Lexicon Pharmaceuticals and Puma Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lexicon Pharmaceuticals position performs unexpectedly, Puma Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Puma Biotechnology will offset losses from the drop in Puma Biotechnology's long position.
The idea behind Lexicon Pharmaceuticals and Puma Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Other Complementary Tools

Share Portfolio
Track or share privately all of your investments from the convenience of any device
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Fundamental Analysis
View fundamental data based on most recent published financial statements
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance